Thermo Fisher Scientific

February 4, 2019
Categories

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
Do you like it?
Read more
January 23, 2018
Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?
Categories

Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

[vc_row][vc_column][vc_column_text]The Food and Drug Administration recently announced the first ever approval of a directly administered gene therapy in the United States. Spark Therapeutics one-time gene therapy […]
Do you like it?
Read more
May 23, 2017
Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon
Categories

Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon

[vc_row][vc_column][vc_column_text] Dutch Contract Development & Manufacturing Organisation Patheon has been acquired by Thermo Fisher Scientific in a $7.2B deal. The acquisition, which includes the assumption of […]
Do you like it?
Read more
April 12, 2017
GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote
Categories

GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

[vc_row][vc_column][vc_column_text]GE Healthcare recently announced the acquisition of British cryogenic processing company Asymptote for an undisclosed price, strengthening its cell therapy portfolio with technologies designed to enable […]
Do you like it?
Read more
March 2, 2017
The Antibody Quality Conundrum: Abcam Ahead of the Curve with Knockout Validation
Categories

The Antibody Quality Conundrum: Abcam Ahead of the Curve with Knockout Validation

[vc_row][vc_column][vc_column_text] In September 2016 the International Working Group for Antibody Validation (IWGAV) finally announced their five conceptual pillars, outlining recommendations to mitigate the antibody specificity and […]
Do you like it?
Read more
12
Next page